Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
publishing date : 2020 - 12 - 15 tags : Phase 3 save search
Sio Gene Therapies Announces Positive Six-Month Follow-Up Data from Low-Dose Cohort of Phase 1/2 Trial of AXO-AAV-GM1 for GM1 Gangliosidosis
Published: 2020-12-15 (Crawled : 21:02) - globenewswire.com
SIOX | $0.478 -20.5% 40K
|
Health Technology
|
| O: 22.18%
H: 19.6%
C: -10.66%
therapy positive gene therapies trial phase 3 phase 1 phase 2 aav9 gene therapy
Celyad Oncology Successfully Doses First Patient in Expansion Cohort of the CYAD-101 Phase 1 alloSHRINK Trial for mCRC
Published: 2020-12-15 (Crawled : 21:01) - globenewswire.com
CYAD | $0.47 -12.49% 49K
|
Health Technology
|
| O: 3.88%
H: 1.08%
C: 0.24%
trial expansion phase 3 phase 1 phase 2
Nektar Therapeutics Announces Dosing of First Patients in Phase 1/2 Study of its IL-15 Agonist, NKTR-255, in Combination with Cetuximab in Patients with Head and Neck Squamous Cell Carcinoma or Colorectal Cancer
Published: 2020-12-15 (Crawled : 16:00) - biospace.com/
NKTR | News | $1.405 -1.06% 290K
|
Health Technology
|
| O: 1.25%
H: 3.5%
C: 3.19%
cancer colorectal cancer phase 3 phase 1 phase 2 cell carcinoma
Zealand Pharma announces data from the first phase 3-trial with dasiglucagon in Congenital Hyperinsulinism (CHI)
Published: 2020-12-15 (Crawled : 14:01) - globenewswire.com
ZEAL | $17.59 1.21% -4.21%
|
Health Technology
|
| O: -10.58%
H: 2.98%
C: 2.97%
insulin phase 3 trial pharma
Novan Exceeds 60% Enrollment in B-SIMPLE4 Pivotal Phase 3 Study of SB206 for Treatment of Molluscum
Published: 2020-12-15 (Crawled : 14:01) - globenewswire.com
NOVN | $0.0941 -24.84% -32.91% 7.2M
|
Health Technology
|
| O: 3.14%
H: 1.5%
C: -2.26%
phase 3 treatment enroll
Gainers vs Losers
| 55% | 45% |
Top 10 Gainers
CZOO | $10.52 110.82% 10M
|
CSSE 4 | $0.3181 108.86% 170M
|
Consumer Services
BOF | $1.88 60.68% 98M
|
AMST | $3.1 55.0% 66M
|
Technology Services
LICN | $0.8592 53.43% 13M
|
WIMI | $1.03 41.99% 15M
|
Technology Services
MULN | News | $3.675 34.62% 11M
|
Information
RILY | $28.605 31.7% 9.9M
|
Finance
RBBN 4 | $3.305 28.6% 1.9M
|
Electronic Technology
RCAT | $1.53 27.5% 2.9M
|
Information
Your saved searches
Save your searches and get alerts when important news are released.